Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD, et al. Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. Diabetes. Mar 2007;56(3):753-766.
One hundred twelve elderly participants exhibiting normal age-related DHEA deficiency were given DHEA (75 mg daily for males and 50 mg daily for females) replacement or placebo for 2 years during which glucose and insulin levels were determined. No improvements in glucose levels or turnover as well as insulin secretion or action were detected. These data argue against the use of DHEA for age-related decline in glucose tolerance. Of note, few of the subjects in this study were obese, so possible positive influences of DHEA in obese individuals could not be determined.
Abrams DI, Shade SB, Couey P, McCune JM, Lo J, Bacchetti P, et al. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses. Jan 2007;23(1):77-85.
The effects of DHEA on HIV replication and overall immune function in 40 HIV-positive participants receiving antiviral therapy were analyzed in this study. Participants either received DHEA (100 and 50 mg twice daily for males and females, respectively) or placebo for 12 weeks followed by a 12-week open label period in which all participants were given DHEA. Although no antiviral or immunostimulatory effects derived from DHEA were detected, DHEA improved the overall quality of life in these subjects. Due to the small sample size and short duration of treatment, a larger, long term analysis is necessary. Furthermore, because only two women were recruited into this study, gender-specific effects of DHEA treatment were not determined.
Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P et al. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology 2003;60:1071-6.
58 volunteers with Alzheimer's disease were randomized to receive DHEA (50 mg twice a day) or placebo for six months. Volunteers were evaluated at three and six months for improvement in cognitive functioning as measured by the AD Assessment Scale-Cognitive as well as observer-based ratings. Researchers did not observe a significant improvement on cognitive performance in the treatment group. Nearly a third of the participants dropped out of the DHEA treatment arm and over half dropped out of the placebo arm.
Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:2924-7.
120 women with active systemic lupus erythematosus were randomized to receive either DHEA (200 mg / day) or placebo for 24 weeks. The main endpoint of the study was change from baseline in the systemic lupus activity measure (SLAM) score at the conclusion of the trial. While women in the treatment group did not experience a significant reduction in SLAM score, the treatment arm did have significantly fewer SLE flares and improved the patient's subjective assessment of disease activity. DHEA was well tolerated in this study, although an increase in acne was observed.